Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dihydropteroate synthetase (DHPS) is a key enzyme in the folate biosynthesis pathway of Plasmodium falciparum. DHPS catalyzes the condensation of para-aminobenzoic acid (pABA) with dihydropterin pyrophosphate to produce dihydropteroate. It is the target of sulfone and sulfonamide drugs like sulfadoxine, used in combination therapies to treat malaria. Resistance arises through point mutations in the dhps gene, particularly A437G, which reduce drug affinity.
Competitive inhibition of DHPS
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dihydropteroate Synthetase (Plasmodium falciparum) (DHPS).